EPIC Act of 2025
- Last Action
- 3/4/2025
Actions
- 2025-03-04Read twice and referred to the Committee on Finance.
- 2025-03-04Introduced in Senate
CRS Summary
As of 2025-03-04 (00)
Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025
This bill lengthens the amount of time for which drug products must have market approval in order for the products to qualify for negotiation under the Medicare Drug Price Negotiation Program.
The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.
The bill modifies these provisions so as to require drug products to also have had at least 11 years of market approval in order to qualify for negotiation beginning in 2028.
Cosponsors (7)
- Ted Budd (R-NC)
- Marsha Blackburn (R-TN)
- Steve Daines (R-MT)
- James Lankford (R-OK)
- John Curtis (R-UT)
- Roger Marshall (R-KS)
- Jim Banks (R-IN)
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.